Key facts
- This page summarizes Loren W. Wass's Form 4 filing for Bionik Laboratories Corp..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 18 Oct 2021, 17:01.
Loren W. Wass - 14 Oct 2021 Form 4 Insider Report for Bionik Laboratories Corp.
- Reporting relationship
- Chief Commercialization Officer
- Issuer ticker
- N/A
- Reported as of
- 14 Oct 2021
- Net transaction value
- $0
- Reporting owner signature
- /s/ Loren Wass
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Loren W. Wass filed Form 4 for Bionik Laboratories Corp. on 18 Oct 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BNKL
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +55,000
- Change %
- Price
- $0.000000
- Shares after
- 55,000
- Date
- 14 Oct 2021
- Ownership
- Direct
- Underlying class
- Common Stock, par value $0.001
- Underlying amount
- 55,000
- Exercise price
- $2.10
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The options vest as follows: 13,750 on the date of grant and on each of October 14, 2022, October 14, 2023 and October 14, 2024.
SEC remarks
Chief Commercialization Officer